The FDA on February 3, 2015 granted accelerated approval to IBRANCE® for use in combination with FEMARA® (Letrozole) for the treatment of postmenopausal women with Estrogen Receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative advanced Breast Cancer, as initial endocrine-based therapy for their metastatic disease. IBRANCE® is a product of Pfizer, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
